Astellas exits Amgen joint venture

Credit: Julia Sudnitskaya

Astellas is selling its shares in its joint venture with Amgen, signing over full control of the strategic alliance to Amgen.

The deal sees Amgen acquire the 49% stake in Amgen Astellas BioPharma owned by Japan’s Astellas, making it a whole-owned Amgen affiliate. It will go by the name of Amgen K.K.

Amgen Astellas BioPharma resulted from a strategic alliance between the two companies in October 2013. Since them, the joint venture has worked alongside Astellas to serve patients in Japan with cardiovascular disease, cancer, and bone disease.

During this time, it launched a number of treatments in Japan – including Repatha for familial hypercholesterolemia (FH) or hypercholesterolemia for patients who have high cardiovascular event risk and do not adequately respond to HMG-CoA reductase inhibitors, Blincyto for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia, and Evenity for osteoporosis patients at high risk of fracture.

Amgen K.K. and Astellas will continue to co-promote these three products and Astellas will remain responsible for distribution and sales of the products beyond 2020.